Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Purchases 317,167 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bvf Partners L. P/Il purchased 317,167 shares of the firm's stock in a transaction on Monday, June 30th. The stock was bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Kymera Therapeutics Stock Up 0.8%

KYMR stock traded up $0.35 during trading on Wednesday, hitting $44.79. 380,187 shares of the company's stock traded hands, compared to its average volume of 629,117. The business has a fifty day simple moving average of $37.73 and a two-hundred day simple moving average of $35.83. The firm has a market capitalization of $2.92 billion, a P/E ratio of -14.45 and a beta of 2.18. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. During the same period in the previous year, the business earned ($0.69) EPS. The firm's revenue for the quarter was up 114.6% on a year-over-year basis. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on KYMR. Jefferies Financial Group set a $64.00 price objective on shares of Kymera Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 25th. UBS Group dropped their target price on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Wells Fargo & Company cut their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, June 26th. JPMorgan Chase & Co. boosted their price objective on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday, June 3rd. Finally, Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price on the stock in a research note on Monday, June 2nd. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $59.61.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of KYMR. KBC Group NV raised its stake in Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after buying an additional 406 shares in the last quarter. Comerica Bank raised its position in shares of Kymera Therapeutics by 3.6% in the first quarter. Comerica Bank now owns 21,374 shares of the company's stock valued at $585,000 after buying an additional 743 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Kymera Therapeutics by 6.1% in the first quarter. Hsbc Holdings PLC now owns 18,547 shares of the company's stock valued at $508,000 after buying an additional 1,064 shares during the last quarter. Finally, State of Wyoming purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $45,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.